David Roth - 03 Apr 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
03 Apr 2024
Net transactions value
-$51,732
Form type
4
Filing time
05 Apr 2024, 16:30:08 UTC
Previous filing
02 Apr 2024
Next filing
04 Nov 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Sale $51,732 -10,451 -100% $4.95 0 03 Apr 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.